Cerebrospinal fluid levels of Alzheimer’s disease biomarkers in middle-aged patients with type 1 diabetes

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Diabetologia

• Publication date

  2014-07-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00125-014-3333-6PMID 25034377
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Michaela Diamant, 11 April 1962–9 April 2014

  2014cited by this paper
• Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span.

  2014cited by this paper
• Resting-State Brain Networks in Type 1 Diabetic Patients With and Without Microangiopathy and Their Relation to Cognitive Functions and Disease Variables

  2012cited by this paper
• The Imbalance of Vascular Molecules in Alzheimer's Disease

  2012influential reference
• Diffusion tensor imaging in type 1 diabetes: decreased white matter integrity relates to cognitive functions

  2012influential reference
• Impaired Lipoprotein Receptor-Mediated Peripheral Binding of Plasma Amyloid-β is an Early Biomarker for Mild Cognitive Impairment Preceding Alzheimer's Disease

  2011cited by this paper
• Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.

  2010cited by this paper
• Amyloid- (cid:1) (1– 42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease

  2010cited by this paper
• How does diabetes accelerate Alzheimer disease pathology?

  2010cited by this paper
• Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes.

  2009cited by this paper
• Functional Brain Connectivity and Neurocognitive Functioning in Patients With Long-Standing Type 1 Diabetes With and Without Microvascular Complications

  2009cited by this paper
• Testing the Neurovascular Hypothesis of Alzheimer's Disease: LRP-1 Antisense Reduces Blood-brain Barrier Clearance, Increases Brain Levels of Amyloid-β Protein, and Impairs Cognition

  2009cited by this paper
• Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease

  2009cited by this paper
• Joint Effect of Hypertension and APOE Genotype on CSF Biomarkers for Alzheimer's Disease

  2009influential reference
• Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.

  2009cited by this paper
• Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

  2009cited by this paper
• Association of the LRP1 gene and cognitive performance with amnestic mild cognitive impairment in elderly Chinese

  2009cited by this paper
• CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

  2009cited by this paper
• Clearance of amyloid-β by circulating lipoprotein receptors

  2007cited by this paper
• Clearance of amyloid-beta by circulating lipoprotein receptors.

  2007cited by this paper
• CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.

  2007cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• Risk of dementia in diabetes mellitus: a systematic review.

  2006cited by this paper
• Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.

  2006cited by this paper
• The effects of type 1 diabetes on cognitive performance: a meta-analysis.

  2005cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003influential reference
• RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

  2003cited by this paper
• Insulin increases CSF Abeta42 levels in normal older adults.

  2003cited by this paper
• Insulin increases CSF Aβ42 levels in normal older adults

  2003cited by this paper
• Amyloid- (cid:98) peptide–Receptor for Advanced Glycation Endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease

  1997cited by this paper

• Phytotherapy for Ageing-Related Multimorbidity: Systems-Level Insights into Centella asiatica in Diabetes and Alzheimer’s Disease

  2026cites this paper
• Metabolic and immune dysfunction at the crossroads between type 1 diabetes and neurodegeneration.

  2025cites this paper
• Multimodal MRI analysis selecting key brain features for machine learning based classification of diabetic neuropathic pain and phenotypes.

  2025cites this paper
• Triptolide induces the secretion of insulin, through which it alleviates the tauopathies of Alzheimer's disease via inhibiting the phosphorylation of tau.

  2025cites this paper
• Hematological and biochemical markers and cytokine levels in hospitalized psychiatric patients with COVID-19

  2025cites this paper
• Role of Tau Protein Hyperphosphorylation in Diabetic Retinal Neurodegeneration

  2025cites this paper
• Increased risk of dementia in Type 1 diabetes: A systematic review with meta-analysis.

  2025cites this paper
• Sugar utilization by microglia in Alzheimer's disease.

  2025cites this paper
• Associations Between Diabetes Mellitus and Neurodegenerative Diseases

  2025cites this paper
• Causal relationships between type 1 diabetes mellitus and Alzheimer’s disease and Parkinson’s disease: a bidirectional two-sample Mendelian randomization study

  2024cites this paper
• Risk factors associated with cognitive performance and cognitive impairment in older adults with type 1 diabetes: Data from the Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) study.

  2024cites this paper
• Association of immune-mediated diseases with the risk of dementia and brain structure in UK Biobank participants.

  2024cites this paper
• Altered surface-based brain morphometry in type 1 diabetes and neuropathic pain.

  2024cites this paper
• ATN blood biomarkers are related to digital cognitive assessment in type 1 diabetes

  2024cites this paper
• Increased incidence of neurodegenerative diseases in Finnish individuals with type 1 diabetes

  2024cites this paper
• The role of EZH2 and its regulatory lncRNAs as a serum-based biomarker in Alzheimer’s disease

  2024cites this paper
• Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer’s disease

  2024cites this paper
• Hyperglycemia enhances brain susceptibility to lipopolysaccharide-induced neuroinflammation via astrocyte reprogramming

  2024cites this paper
• Biomarkers of Neurodegeneration and Alzheimer’s Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study

  2024cites this paper
• Neuroprotective effect of the traditional decoction Tian-Si-Yin against Alzheimer's disease via suppression of neuroinflammation.

  2023cites this paper
• Metabolic Profile of Alzheimer’s Disease: Is 10-Hydroxy-2-decenoic Acid a Pertinent Metabolic Adjuster?

  2023cites this paper
• P38 initiates degeneration of midbrain GABAergic and glutamatergic neurons in diabetes models

  2022cites this paper
• Immune-mediated diseases are associated with a higher incidence of dementia: a prospective cohort study of 375,894 individuals

  2022cites this paper
• Nutritional intervention for diabetes mellitus with Alzheimer's disease

  2022cites this paper
• Soluble LRP-1 in Parkinson’s disease: clues for paradoxical effects

  2022cites this paper
• Dementia in Diabetes mellitus and Atherosclerosis; Two Interrelated Systemic Diseases.

  2022cites this paper
• Network-based analysis on genetic variants reveals the immunological mechanism underlying Alzheimer’s disease

  2021cites this paper
• The Dual Role of Low-Density Lipoprotein Receptor-Related Protein 1 in Atherosclerosis

  2021cites this paper
• Cognitive Functioning and Hippocampal Connectivity in Patients With Longstanding Type 1 Diabetes and Apolipoprotein E ε4

  2021cites this paper
• Cerebral Microvascular Disease in Diabetes – Clinical and Research

  2020cites this paper
• Analysis of risk factors for depression in Alzheimer’s disease patients

  2020cites this paper
• Insulin deficiency promotes formation of toxic amyloid-β42 conformer co-aggregating with hyper-phosphorylated tau oligomer in an Alzheimer's disease model.

  2020cites this paper
• Shared signaling pathways in Alzheimer’s and metabolic disease may point to new treatment approaches

  2020cites this paper
• Neurocognitive Functioning in Type 1 and Type 2 Diabetes Mellitus

  2020cites this paper
• Tau, Diabetes and Insulin.

  2019cites this paper
• Cognitive Dysfunctions in Type 1 Diabetes

  2019cites this paper
• Role of the Blood-Brain Barrier in Central Nervous System Insulin Resistance

  2019cites this paper
• Docosahexaenoic Acid Increases the Potency of Soluble Epoxide Hydrolase Inhibitor in Alleviating Streptozotocin-Induced Alzheimer’s Disease-Like Complications of Diabetes

  2019cites this paper
• A Possible Neurodegeneration Mechanism Triggered by Diabetes.

  2019cites this paper
• Diabetes as a risk factor for Alzheimer’s disease in the Middle East and its shared pathological mediators

  2019cites this paper
• Importance of Treatment Status in Links Between Type 2 Diabetes and Alzheimer’s Disease

  2019cites this paper
• Cognitive Dysfunction in Type 1 Diabetes Mellitus.

  2019cites this paper
• Changes in Cerebrospinal Fluid Tau and β-Amyloid Levels in Diabetic and Prediabetic Patients: A Meta-Analysis

  2018cites this paper
• Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants

  2017cites this paper
• IRS 2 Insulin receptor substrate-2

  2017influential citation
• Type II Diabetes and Metabolic Syndrome as Risk Factors for Alzheimer’s Disease

  2017cites this paper
• Tauopathy and cognitive impairment in experimental diabetes mellitus

  2017cites this paper
• Type 1 diabetes in older age

  2017cites this paper
• The diabetic brain and cognition

  2017cites this paper
• Disrupted subject‐specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy

  2016cites this paper
• Reciprocal Molecular Interactions between the Aβ Peptide Linked to Alzheimer's Disease and Insulin Linked to Diabetes Mellitus Type II.

  2016cites this paper
• Subgenual Cingulate Cortex Functional Connectivity in Relation to Depressive Symptoms and Cognitive Functioning in Type 1 Diabetes Mellitus Patients

  2016cites this paper
• The Rationale for Insulin Therapy in Alzheimer’s Disease

  2016cites this paper
• Peripheral Levels of AGEs and Astrocyte Alterations in the Hippocampus of STZ-Diabetic Rats

  2016cites this paper
• Can insulin signaling pathways be targeted to transport Aβ out of the brain?

  2015cites this paper
• The Impact of Diabetes on Brain Function in Childhood and Adolescence.

  2015cites this paper
• Soluble Megalin is Reduced in Cerebrospinal Fluid Samples of Alzheimer’s Disease Patients

  2015cites this paper